First human tests begin for experimental cancer immunotherapy duo
NCT ID NCT02988960
Summary
This is an early-stage study to find the safest and most effective doses of two new immunotherapy drugs, ABBV-927 and ABBV-181, for people with advanced solid tumors. The study will test the drugs alone and together in about 163 participants whose cancer has progressed after standard treatments. The main goals are to understand how the body processes the drugs and to check for side effects, while also looking for early signs that the treatment might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Austin Health /ID# 171189
Heidelberg, Victoria, 3084, Australia
-
Carolina BioOncology Institute /ID# 155265
Huntersville, North Carolina, 28078, United States
-
Centre Leon Berard /ID# 162663
Lyon, Rhone, 69373, France
-
Duplicate_Institut Regional du Cancer /ID# 163609
Montpellier, Herault, 34298, France
-
Hospital Universitario Fundacion Jimenez Diaz /ID# 200128
Madrid, 28040, Spain
-
Hospital Universitario HM Sanchinarro /ID# 200127
Madrid, 28050, Spain
-
Hospital Universitario Puerta de Hierro - Majadahonda /ID# 200129
Majadahonda, Madrid, 28222, Spain
-
Hospital Universitario y Politecnico La Fe /ID# 200975
Valencia, 46026, Spain
-
Institut Bergonie /ID# 162665
Bordeaux, Gironde, 33000, France
-
Institut Gustave Roussy /ID# 162666
Villejuif, Val-de-Marne, 94805, France
-
Massachusetts General Hospital /ID# 155267
Boston, Massachusetts, 02114, United States
-
National Cancer Center Hospital /ID# 217758
Chuo-ku, Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East /ID# 216870
Kashiwa-shi, Chiba, 277-8577, Japan
-
Peninsula Oncology Centre /ID# 164372
Frankston, Victoria, 3199, Australia
-
Seoul National University Hospital /ID# 166291
Seoul, Seoul Teugbyeolsi, 03080, South Korea
-
Tennessee Oncology-Nashville Centennial /ID# 158654
Nashville, Tennessee, 37203-1632, United States
-
The Angeles Clinic and Researc /ID# 156324
Los Angeles, California, 90025, United States
-
The University of Chicago Medical Center /ID# 155264
Chicago, Illinois, 60637-1443, United States
-
University Health Network_Princess Margaret Cancer Centre /ID# 200819
Toronto, Ontario, M5G 2M9, Canada
-
University of Texas MD Anderson Cancer Center /ID# 155263
Houston, Texas, 77030, United States
-
Virginia Cancer Specialists - Fairfax /ID# 155266
Fairfax, Virginia, 22031, United States
-
Yonsei University Health System Severance Hospital /ID# 166292
Seoul, 03722, South Korea
Conditions
Explore the condition pages connected to this study.